Response Evaluation of Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma with Respect to Tumour Size, Number of Lesion, and Alpha-Fetoprotein (AFP) Level
Background: Transarterial chemoembolization (TACE) is widely used as a palliative treatment for unresectable hepatocellular carcinoma (HCC). TACE is also used as bridging therapy before liver transplantation to avoid tumour progression and considered for downstaging to fulfill tumour resection or li...
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Interna Publishing
2016-05-01
|
| シリーズ: | The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy |
| 主題: | |
| オンライン･アクセス: | http://ina-jghe.com/journal/index.php/jghe/article/view/516/439 |
| _version_ | 1831608622935703552 |
|---|---|
| author | Adaninggar PN Ulfa Kholili Ummi Maimunah Poernomo B Setiawan Iswan A Nusi Herrry Purbayu Titong Sugihartono Budi Widodo Husin Thamrin Amie Vidyani |
| author_facet | Adaninggar PN Ulfa Kholili Ummi Maimunah Poernomo B Setiawan Iswan A Nusi Herrry Purbayu Titong Sugihartono Budi Widodo Husin Thamrin Amie Vidyani |
| author_sort | Adaninggar PN |
| collection | DOAJ |
| description | Background: Transarterial chemoembolization (TACE) is widely used as a palliative treatment for unresectable hepatocellular carcinoma (HCC). TACE is also used as bridging therapy before liver transplantation to avoid tumour progression and considered for downstaging to fulfill tumour resection or liver transplantation criterias. This study aimed to evaluate response of TACE in unresectable HCC according to changing of tumour size, number of lesion, and AFP level.
Method: Retrospectively, we evaluate 69 HCC patients who underwent TACE in Dr. Soetomo General Hospital in January 2012-June 2015, including their age, sex, aetiologies, and Barcelona Clinic Liver Cancer/BCLC staging. Laboratory examinations such as complete blood count (hemoglobin/Hb, leucocyte, thrombocyte), liver function test (aspartate aminotransferase/AST, alanine aminotransferase/ALT, bilirubin, albumin, international normalized ratio/INR), alpha-fetoprotein/AFP level, and abdominal CT-scan were performed before and 1 month post-TACE. Data was analysed using paired t-test.
Results: 69 patients with mean age of 51.81 12.8 years old, predominantly 76.8% males, the most common aetiology was hepatitis B 68.1%, 92.8% BCLC B, 64.3% with stable disease, none achieved complete response, 97.1% had tumour size > 5 cm, 69.6% had single tumour, and 55.7% had AFP level >1000 ng/mL. There was a significant increase in tumour size and number of lesions in 1 month post-TACE that were approximately 1.76 cm and 2.33, respectively, and there was no significant difference between AFP level before and 1 month post TACE.
Conclusion: In 1 month post TACE evaluation, there was a significant increase of tumour size and number of lesion, but there was no significant alteration in AFP level. TACE might be performed repeatedly with shorter evaluation interval than 1 month to achieve better response. |
| first_indexed | 2024-12-18T17:48:31Z |
| format | Article |
| id | doaj.art-6a6d9e90beab43e68b5f9b4abf7ba7aa |
| institution | Directory Open Access Journal |
| issn | 1411-4801 2302-8181 |
| language | English |
| last_indexed | 2024-12-18T17:48:31Z |
| publishDate | 2016-05-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy |
| spelling | doaj.art-6a6d9e90beab43e68b5f9b4abf7ba7aa2022-12-21T20:58:56ZengInterna PublishingThe Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy1411-48012302-81812016-05-0117139Response Evaluation of Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma with Respect to Tumour Size, Number of Lesion, and Alpha-Fetoprotein (AFP) LevelAdaninggar PN0Ulfa Kholili1Ummi Maimunah2Poernomo B Setiawan3Iswan A Nusi4Herrry Purbayu5Titong Sugihartono6Budi Widodo7Husin Thamrin8Amie Vidyani9Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo General Hospital, SurabayaDivision of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo General Hospital, SurabayaDivision of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo General Hospital, SurabayaDivision of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo General Hospital, SurabayaDivision of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo General Hospital, SurabayaDivision of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo General Hospital, SurabayaDivision of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo General Hospital, SurabayaDivision of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo General Hospital, SurabayaDivision of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo General Hospital, SurabayaDivision of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo General Hospital, SurabayaBackground: Transarterial chemoembolization (TACE) is widely used as a palliative treatment for unresectable hepatocellular carcinoma (HCC). TACE is also used as bridging therapy before liver transplantation to avoid tumour progression and considered for downstaging to fulfill tumour resection or liver transplantation criterias. This study aimed to evaluate response of TACE in unresectable HCC according to changing of tumour size, number of lesion, and AFP level. Method: Retrospectively, we evaluate 69 HCC patients who underwent TACE in Dr. Soetomo General Hospital in January 2012-June 2015, including their age, sex, aetiologies, and Barcelona Clinic Liver Cancer/BCLC staging. Laboratory examinations such as complete blood count (hemoglobin/Hb, leucocyte, thrombocyte), liver function test (aspartate aminotransferase/AST, alanine aminotransferase/ALT, bilirubin, albumin, international normalized ratio/INR), alpha-fetoprotein/AFP level, and abdominal CT-scan were performed before and 1 month post-TACE. Data was analysed using paired t-test. Results: 69 patients with mean age of 51.81 12.8 years old, predominantly 76.8% males, the most common aetiology was hepatitis B 68.1%, 92.8% BCLC B, 64.3% with stable disease, none achieved complete response, 97.1% had tumour size > 5 cm, 69.6% had single tumour, and 55.7% had AFP level >1000 ng/mL. There was a significant increase in tumour size and number of lesions in 1 month post-TACE that were approximately 1.76 cm and 2.33, respectively, and there was no significant difference between AFP level before and 1 month post TACE. Conclusion: In 1 month post TACE evaluation, there was a significant increase of tumour size and number of lesion, but there was no significant alteration in AFP level. TACE might be performed repeatedly with shorter evaluation interval than 1 month to achieve better response.http://ina-jghe.com/journal/index.php/jghe/article/view/516/439hepatocellular carcinomatransarterial chemoembolizationalpha fetoproteintumour sizenumber of lesion |
| spellingShingle | Adaninggar PN Ulfa Kholili Ummi Maimunah Poernomo B Setiawan Iswan A Nusi Herrry Purbayu Titong Sugihartono Budi Widodo Husin Thamrin Amie Vidyani Response Evaluation of Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma with Respect to Tumour Size, Number of Lesion, and Alpha-Fetoprotein (AFP) Level The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy hepatocellular carcinoma transarterial chemoembolization alpha fetoprotein tumour size number of lesion |
| title | Response Evaluation of Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma with Respect to Tumour Size, Number of Lesion, and Alpha-Fetoprotein (AFP) Level |
| title_full | Response Evaluation of Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma with Respect to Tumour Size, Number of Lesion, and Alpha-Fetoprotein (AFP) Level |
| title_fullStr | Response Evaluation of Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma with Respect to Tumour Size, Number of Lesion, and Alpha-Fetoprotein (AFP) Level |
| title_full_unstemmed | Response Evaluation of Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma with Respect to Tumour Size, Number of Lesion, and Alpha-Fetoprotein (AFP) Level |
| title_short | Response Evaluation of Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma with Respect to Tumour Size, Number of Lesion, and Alpha-Fetoprotein (AFP) Level |
| title_sort | response evaluation of patients undergoing transarterial chemoembolization tace for hepatocellular carcinoma with respect to tumour size number of lesion and alpha fetoprotein afp level |
| topic | hepatocellular carcinoma transarterial chemoembolization alpha fetoprotein tumour size number of lesion |
| url | http://ina-jghe.com/journal/index.php/jghe/article/view/516/439 |
| work_keys_str_mv | AT adaninggarpn responseevaluationofpatientsundergoingtransarterialchemoembolizationtaceforhepatocellularcarcinomawithrespecttotumoursizenumberoflesionandalphafetoproteinafplevel AT ulfakholili responseevaluationofpatientsundergoingtransarterialchemoembolizationtaceforhepatocellularcarcinomawithrespecttotumoursizenumberoflesionandalphafetoproteinafplevel AT ummimaimunah responseevaluationofpatientsundergoingtransarterialchemoembolizationtaceforhepatocellularcarcinomawithrespecttotumoursizenumberoflesionandalphafetoproteinafplevel AT poernomobsetiawan responseevaluationofpatientsundergoingtransarterialchemoembolizationtaceforhepatocellularcarcinomawithrespecttotumoursizenumberoflesionandalphafetoproteinafplevel AT iswananusi responseevaluationofpatientsundergoingtransarterialchemoembolizationtaceforhepatocellularcarcinomawithrespecttotumoursizenumberoflesionandalphafetoproteinafplevel AT herrrypurbayu responseevaluationofpatientsundergoingtransarterialchemoembolizationtaceforhepatocellularcarcinomawithrespecttotumoursizenumberoflesionandalphafetoproteinafplevel AT titongsugihartono responseevaluationofpatientsundergoingtransarterialchemoembolizationtaceforhepatocellularcarcinomawithrespecttotumoursizenumberoflesionandalphafetoproteinafplevel AT budiwidodo responseevaluationofpatientsundergoingtransarterialchemoembolizationtaceforhepatocellularcarcinomawithrespecttotumoursizenumberoflesionandalphafetoproteinafplevel AT husinthamrin responseevaluationofpatientsundergoingtransarterialchemoembolizationtaceforhepatocellularcarcinomawithrespecttotumoursizenumberoflesionandalphafetoproteinafplevel AT amievidyani responseevaluationofpatientsundergoingtransarterialchemoembolizationtaceforhepatocellularcarcinomawithrespecttotumoursizenumberoflesionandalphafetoproteinafplevel |